Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy

Michael F. Emmons, Fernanda Faião-Flores, Ritin Sharma, Ram Thapa, Jane L. Messina, Jurgen C. Becker, Dirk Schadendorf, Edward Seto, Vernon K. Sondak, John M. Koomen, Yian A. Chen, Eric K. Lau, Lixin Wan, Jonathan D. Licht, Keiran S.M. Smalley

Cancer Res (2019) 79 (11): 2947–2961.

https://doi.org/10.1158/0008-5472.CAN-19-0040

Published: 03 June 2019

View article titled, HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy

Includes: Supplementary data

Journal Articles

Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Hua Yang, Michael F. Emmons, Christopher Cubitt, Ken Shain, Domenico Coppola, Daniel Sullivan, Conor C. Lynch, Lori Hazlehurst, Said M. Sebti

Cancer Res (2015) 75 (15_Supplement): 2605.

https://doi.org/10.1158/1538-7445.AM2015-2605

Published: 01 August 2015

View article titled, Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Journal Articles

Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens

Michael F. Emmons, Anthony Gebhard, Mark Mclaughlin, Anne Cress, Lori Hazlehurst

Cancer Res (2011) 71 (8_Supplement): 1523.

https://doi.org/10.1158/1538-7445.AM2011-1523

Published: 15 April 2011

View article titled, Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens

Journal Articles

Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma

Anthony W. Gebhard, Michael F. Emmons, Raul F. Argilagos, Mark McLaughlin, John Koomen, Anne E. Cress, Lori A. Hazlehurst

Cancer Res (2011) 71 (8_Supplement): 3628.

https://doi.org/10.1158/1538-7445.AM2011-3628

Published: 15 April 2011

View article titled, Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma

Journal Articles

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Joel G. Turner, Douglas C. Marchion, Jana L. Dawson, Michael F. Emmons, Lori A. Hazlehurst, Peter Washausen, Daniel M. Sullivan

Cancer Res (2009) 69 (17): 6899–6905.

https://doi.org/10.1158/0008-5472.CAN-09-0484

Published: 31 August 2009

View article titled, Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Journal Articles

CRM1 knockdown by ratjadone C, leptomycin B, and siRNA to CRM1, enhance sensitivity of human multiple myeloma cells to topoisomerase II inhibitors.

Joel G. Turner, Douglas C. Marchion, Edward R. Seijo, Michael F. Emmons, Lori A. Hazlehurst, Pamela N. Munster, Peter Washausen, Daniel M. Sullivan

Cancer Res (2006) 66 (8_Supplement): 1277.

Published: 15 April 2006

View article titled, CRM1 knockdown by ratjadone C, leptomycin B, and siRNA to CRM1, enhance sensitivity of human multiple myeloma cells to topoisomerase II inhibitors.

Journal Articles

Adhesion of U937 to FN increases the levels and rates of resistance and alters the mechanisms associated with acquired mitoxantrone resistance

Lori A. Hazlehurst, Raul F. Argilagos, Michael F. Emmons, William S. Dalton

Cancer Res (2005) 65 (9_Supplement): 1400.

Published: 01 May 2005

View article titled, Adhesion of U937 to FN increases the levels and rates of resistance and alters the mechanisms associated with acquired mitoxantrone resistance

NARROW

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy

Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens

Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

CRM1 knockdown by ratjadone C, leptomycin B, and siRNA to CRM1, enhance sensitivity of human multiple myeloma cells to topoisomerase II inhibitors.

Adhesion of U937 to FN increases the levels and rates of resistance and alters the mechanisms associated with acquired mitoxantrone resistance

Email alerts

AACR Journals

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy

Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model

Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens

Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

CRM1 knockdown by ratjadone C, leptomycin B, and siRNA to CRM1, enhance sensitivity of human multiple myeloma cells to topoisomerase II inhibitors.

Adhesion of U937 to FN increases the levels and rates of resistance and alters the mechanisms associated with acquired mitoxantrone resistance

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only